Boult Wade Tennant
People » Dr Joanna Peak

Dr Joanna Peak

Partner

London

Contact
Download V-card
Address
Memberships
  • AIPPI
  • CIPA
Qualifications
  • Registered UPC Representative
  • European Patent Attorney
  • Chartered Patent Attorney
  • Certificate in Intellectual Property Law, Queen Mary University of London
  • PhD, University of London
  • MSci Biochemistry, University of Cambridge
  • MA Cantab Natural Sciences, University of Cambridge

I am a Partner with Boult and work with a diverse range of clients in the biotechnology and life sciences sector.

My clients range from universities and SMEs through to multinational pharmaceutical companies. I assist my clients with patent matters spanning many different areas of biotechnology. These include therapeutic antibodies, immuno-oncology, gene editing, stem cell therapies and nutritional products.

I have a scientific background in translational research having completed a PhD at the Institute of Cancer Research (ICR) prior to entering the IP profession. My time at the ICR gave me first-hand experience of the drug development process and the challenges faced by those working in this field. The ultimate goal of bringing successful treatments to the market remains important to me and I feel that my background in research assists me greatly in aligning my clients’ patent strategy with their clinical and commercial objectives. In this regard, I am experienced at patent drafting, prosecution and advising my clients with respect to freedom to operate and infringement issues.

I also enjoy representing my clients in contentious proceedings before the European Patent Office. For several years, I have successfully defended my clients’ patents and challenged third party patents before the EPO’s opposition divisions and Boards of Appeal. My cases are often complex from both a technical and legal standpoint and I enjoy working closely with my clients throughout the process to try to achieve the desired result.

I am supported in my work by my biotech and pharma colleagues, and it is a privilege to work alongside such talented individuals. We regularly share thoughts and ideas and I feel that our collaborative approach is of real benefit to our clients. It also provides a strong environment for training and supervision, and I find it very rewarding sharing my experiences so as to support others in their career development.

Recent experience

Successfully defending a European patent for a pharma company developing stem cell therapies in opposition proceedings before the EPO.

Testimonials and recognitions
  • CIPA Drafting Prize
Publications
Relevant Search Terms
Recommended Sites
Suggested Media
Recognitions
Additional Info
Languages
“The ultimate goal of bringing successful treatments to the market remains important to me and I feel that my background in research assists me greatly in aligning my clients’ patent strategy with their clinical and commercial objectives.”
Sector Experience
Biotechnology
  • Antibody engineering
  • Antibody manufacture and formulation
  • Biosimilars
  • Drug delivery
  • Gene editing (e.g. CRISPR)
  • Genomic and molecular tools and methods
  • Immuno-oncology (e.g. checkpoint inhibitors; modified T cells)
  • Personalised medicine/disease biomarkers
  • Recombinant protein production and purification
  • Stem cell therapies
  • Supplementary protection certificates (SPCs)
  • Synthetic biology
  • Therapeutic antibodies
  • Vaccinology (e.g. viral vectors; mRNA vaccines)
  • Women’s health products
Food and beverage
  • Nutrition
Pharmaceuticals
  • Drug delivery
  • Generic market entry
  • Personalised medicine/disease biomarkers
  • Small molecule pharmaceuticals
  • Supplementary protection certificates (SPCs)

I am a Partner with Boult and work with a diverse range of clients in the biotechnology and life sciences sector.

My clients range from universities and SMEs through to multinational pharmaceutical companies. I assist my clients with patent matters spanning many different areas of biotechnology. These include therapeutic antibodies, immuno-oncology, gene editing, stem cell therapies and nutritional products.

I have a scientific background in translational research having completed a PhD at the Institute of Cancer Research (ICR) prior to entering the IP profession. My time at the ICR gave me first-hand experience of the drug development process and the challenges faced by those working in this field. The ultimate goal of bringing successful treatments to the market remains important to me and I feel that my background in research assists me greatly in aligning my clients’ patent strategy with their clinical and commercial objectives. In this regard, I am experienced at patent drafting, prosecution and advising my clients with respect to freedom to operate and infringement issues.

I also enjoy representing my clients in contentious proceedings before the European Patent Office. For several years, I have successfully defended my clients’ patents and challenged third party patents before the EPO’s opposition divisions and Boards of Appeal. My cases are often complex from both a technical and legal standpoint and I enjoy working closely with my clients throughout the process to try to achieve the desired result.

I am supported in my work by my biotech and pharma colleagues, and it is a privilege to work alongside such talented individuals. We regularly share thoughts and ideas and I feel that our collaborative approach is of real benefit to our clients. It also provides a strong environment for training and supervision, and I find it very rewarding sharing my experiences so as to support others in their career development.

Recent experience

Successfully defending a European patent for a pharma company developing stem cell therapies in opposition proceedings before the EPO.

Testimonials and recognitions
  • CIPA Drafting Prize
Publications
Relevant Search Terms
Recommended Sites
Suggested Media
Recognitions
Additional Info

Insights

image
UPC

UPC Central Division revokes an antibody patent in landmark first decision on the merits

More
image
Bulletin

The CJEU rules against second medical use SPCs

More
image
Bulletin

G2/21.

More
image
Bulletin

Clinical trials and prior disclosure – a difficult balancing act for patentees.

More
image
Bulletin

Plausibility and Post-Published Evidence (G2/21).

More
image
Bulletin

The EPO rules that plants and animals exclusively obtained by essentially biological processes are not patentable

More
INSIGHTS